CERA conversion to darbepoetin alfa in 154 hemodialysis patients.
Fiche publication
Date publication
juillet 2020
Journal
International urology and nephrology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MEYER Nicolas
Tous les auteurs :
Dimitrov Y, Rieger J, Krummel T, Petitjean P, Klein A, Chantrel F, Meyer N, Hannedouche T
Lien Pubmed
Résumé
Anemia is a common complication in dialysis patients, usually treated with erythropoietin (EPO). Among available EPOs and analogs, continuous erythropoietin receptor activator (CERA) and darbepoetin alfa (DA) are the only two agents with a long duration of action, although they have almost never been formally compared in terms of efficacy. We took advantage of an accidental disruption in CERA supply to study the effect of its replacement with DA in the same patients.
Mots clés
Anemia, CERA, Darbopoetin alpha, Dialysis, ESA
Référence
Int Urol Nephrol. 2020 Jul 28;: